person
Alessandro A.
- Country
- Italy
- Department
- Dipartimento di Gastroenterologia
Research Overview
assignment
67
Clinical Trials ·
- A randomized, double-blind, placebo controlled, dose finding study to assess the efficacy and safety of SAR443122 in adult patients with moderate to severe ulcerative colitis
- Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Duvakitug for Induction Therapy in Moderately to Severely Active Crohn's Disease
- Efficacy and Safety of Duvakitug for Maintenance Therapy in Participants with Moderately to Severely Active Crohn’s Disease: A Phase 3, Randomized, Placebo-Controlled Study
location_city
2
Research Sites
Data & Insights
medical_services
Primary Speciality
Main therapeutic area
handshake
Return Partnerships
Recurring site collaborations
565
Sites with multiple studies
Has run more than one trial at 565 of 816 partner sites.
Specializations
Inflammatory Bowel Disease Research
This investigator specializes in studying novel therapeutic approaches for inflammatory bowel disease (IBD), with particular emphasis on both ulcerative colitis and Crohn's disease treatments.
- Moderate to Severe Ulcerative Colitis Management
- Advanced Crohn's Disease Therapeutics
- Long-term Treatment Outcomes
Specialized Conditions
The investigator focuses on complex manifestations of IBD, including fibrostenotic Crohn's disease and fistulizing perianal Crohn's disease.
- Post-operative Disease Management
- Endoscopic Disease Assessment
- Therapeutic Response Evaluation
Treatment Innovation
Active involvement in evaluating novel therapeutic compounds and biological therapies for inflammatory bowel conditions.
- Maintenance Therapy Development
- Induction Treatment Protocols
- Clinical Response Assessment
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.